Exosomes have incredible properties that enable researchers to engineer exosomes as carriers for the delivery of drugs and target tissues of interest, while evading or modulating immune responses. Drug delivery and development of exosome-mediated therapies is a growing market segment, with over 50 companies forging ahead in this field. All the recent advances in exosome research are technology-based and this helps researchers to quantify exosome cargoes and subtypes, allowing for the tracking of exosomes with remarkable precision. This is helping companies to regulate exosome drug dosage and delivery, as well as deliver effective treatments for hard-to-treat diseases, such as cancer and neurodegenerative diseases. [Read more…]
Bayer and Evotec to Develop Precision Cardiology Therapeutics Using iPSC-based Disease Modelling
Bayer and Evotec Update Focus of their Collaboration to Cardiovascular Diseases
Strategic Alliance will Leverage Human iPSC Disease Modelling for Identification of Novel Targets
Berlin and Hamburg, Germany, 30 April 2024 – Bayer and the German-based life science company, Evotec, announced today that they have updated the focus of their strategic collaboration to developing innovative precision treatments for cardiovascular diseases (CVDs). [Read more…]
AABB Releases New Resources and Initiatives For its Certified Advanced Biotherapies Professional (CABP) Program
May 1, 2024, Bethesda, MD – The Association for the Advancement of Blood & Biotherapies (AABB) is pleased to announce several new offerings as part of its Certified Advanced Biotherapies Professional (CABP) credentialing program. These updates, released to make the CABP program more accessible to biotherapies professionals and organizations, include: [Read more…]
Allogeneic iPSCs Gaining Momentum Due to Ease of Access and Economies of Scale
While autologous iPSC-based cell therapies are patient-specific, allogeneic iPSC-based cell therapies use donor-derived cells as a starting material. In recent years, a greater number of allogeneic iPSC-derived cell therapies are being studied than autologous therapies. One of the advantages of allogeneic therapy is that a large number of doses can be generated simultaneously from a single batch of iPSCs and banked. [Read more…]
Century Therapeutics Raises $60 Million, Acquires Clade Therapeutics, and Expands Pipeline of Allogeneic, iPSC-Derived Cellular Therapies
Century is pursuing additional autoimmune disease regulatory filings for its iPSC derived iNK cell therapy, CNTY-101, beyond CALiPSO-1 trial in SLE, based on the potential of its differentiated profile
Private placement of $60 million led by Bain Capital Life Sciences supports expansion in autoimmune disease; Reinforcing cash runway into 2026
Acquisition of Clade Therapeutics strengthens Century’s position as a leader in allogeneic, iPSC-derived cell therapy through enhancement of pipeline and next generation Allo-EvasionTM platform
Newly expanded pipeline incorporates three additional preclinical-stage programs from Clade’s αβ iT platform spanning across cancer and autoimmune diseases
- « Previous Page
- 1
- …
- 94
- 95
- 96
- 97
- 98
- …
- 334
- Next Page »